drugset / Trial / NCT05372120
A Clinical Trial of ICP-192 in Treated Patients With Advanced Solid Tumors With FGF/FGFR Gene Alterations
NaSingle-groupOpen-labelTreatment
Summary
This is a phase II clinical trial in treated patients with advanced solid tumors with FGF/FGFR gene alterations. The purpose of this study is to evaluate the efficacy and safety of ICP-192.
Timeline
- Start
- 2021-12-15
- Primary completion
- 2023-12-31
- Completion
- 2024-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ICP-192 | Unknown | 20 mg | Oral |